Thermo Fisher Scientific CD30 Chimeric Recombinant Rabbit Monoclonal Antibody (Ki-4)

Applications

Product Specifications

Product Specific Information

Specificity: The antibody binds to CD30.

Target Information

CD30 (Ki-1, TNF Receptor Superfamily Member 8) is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkin’s and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death.

CD30 plays a critical role in the pathophysiology of Hodgkin’s disease and other CD30+ lymphomas. It acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkin’s and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin’s lymphomas (including Burkitt’s lymphomas), virus-infected T and B cells, and on normal T and B cells after activation.

In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. The soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response. TRAF2 and TRAF5 can interact with this receptor and mediate signal transduction leading to NF-kappaB activation. CD30 is a positive regulator of apoptosis and has been shown to limit the proliferative potential of autoreactive CD8 effector T cells, thereby protecting against autoimmunity. Two alternatively spliced transcript variants encoding distinct isoforms have been reported. CD30 is expressed by mononuclear cells in Hodgkin’s lymphoma, Reed-Sternberg cells, and most Anaplastic Large Cell Lymphomas (ALCL). It is also expressed by embryonal carcinomas.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.